A recent report from our group showed that pharmacological and genetic inhibition of the MEK5–ERK5 pathway reduces the growth of CML-patient-derived cells and cell lines in vitro and the number of leukemic cells in a CML mouse model [35]. This evidence concerns the gene MAP2K5 and chronic myelogenous leukemia, BCR-ABL1 positive.